What does PHARMATEL do?

PHARMATEL is registered with the CBE as active in: Activiteiten van holdings. Public Limited, started on 11 June 2013, 1 establishment.

What is the address of PHARMATEL?

The registered office of PHARMATEL is located at Surkelbulk 8, 9051 Gent.

Is PHARMATEL still active?

Yes. According to the CBE (29 October 2026) PHARMATEL is active, legal situation “Normale toestand”, started on 11 June 2013.

Is PHARMATEL registered on Peppol?

Yes, PHARMATEL is registered on the Peppol network with ID 0208:0535844727.

What is the enterprise number of PHARMATEL?

The enterprise number of PHARMATEL is BE0535844727.

When was PHARMATEL founded?

PHARMATEL was founded on 11 June 2013.

Who are the directors of PHARMATEL?

According to the 2025 annual accounts, the directors of PHARMATEL are: Harry Christiaens, Lieven Van Vooren, YACELO NV.

Is PHARMATEL a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 June 2013; 4 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did PHARMATEL make in 2025?

PHARMATEL posted a profit after taxes of € 429,692 in financial year 2025.

What is the revenue of PHARMATEL?

As a small company, PHARMATEL is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 6,028.

PHARMATEL (Public Limited) - Gent - BE0535844727

Dossier PHARMATEL, printed on 29 October 2026 from databakkes.be/en/0535844727/pharmatel. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 28 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMATEL from Gent, company number BE0535844727, closed financial year 2025 with a result of € 429,692 after tax. For that financial year PHARMATEL recorded a gross margin of € 6,028 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 30,595 to € 429,692. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 16, 2025.

What it is worth Healthy

€ 1.1 million

▼ 49% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 429,692

▲ € 399,097 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 26,679

▼ 88% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1.5 million paid out

More than the year’s profit went to the shareholders; reserves fell.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Taxes

€ 496

▲ 11% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 11,899 Gross margin 2022: € 11,899 First fiscal year in the series	€ 2,482 Gross margin 2023: € 2,482 ▼ 79% vs 2022 (€ 11,899) Unfavourable step	€ 4,521 Gross margin 2024: € 4,521 ▲ 82% vs 2023 (€ 2,482) Favourable step	€ 6,028 Gross margin 2025: € 6,028 ▲ 33% vs 2024 (€ 4,521) Favourable step	▲ 33%
Profit after taxes	€ 31,804 Profit after taxes 2022: € 31,804 First fiscal year in the series	€ 1,815 Profit after taxes 2023: € 1,815 ▼ 94% vs 2022 (€ 31,804) Unfavourable step	€ 30,595 Profit after taxes 2024: € 30,595 ▲ € 28,780 vs 2023 (€ 1,815) Favourable step	€ 429,692 Profit after taxes 2025: € 429,692 ▲ € 399,097 vs 2024 (€ 30,595) Favourable step	▲ € 399,097
Equity	€ 2,430,999 Equity 2022: € 2,430,999 First fiscal year in the series	€ 2,432,814 Equity 2023: € 2,432,814 Unchanged (€ 2,430,999) Favourable step	€ 2,103,409 Equity 2024: € 2,103,409 ▼ 14% vs 2023 (€ 2,432,814) Unfavourable step	€ 1,071,201 Equity 2025: € 1,071,201 ▼ 49% vs 2024 (€ 2,103,409) Unfavourable step	▼ 49%
Total debts	€ 476 Total debts 2022: € 476 First fiscal year in the series	€ 1,084 Total debts 2023: € 1,084 ▲ 127% vs 2022 (€ 476) Unfavourable step	€ 242,858 Total debts 2024: € 242,858 ▲ € 241,774 vs 2023 (€ 1,084) Unfavourable step	€ 562,461 Total debts 2025: € 562,461 ▲ 132% vs 2024 (€ 242,858) Unfavourable step	▲ 132%
Cash	€ 102,426 Cash 2022: € 102,426 First fiscal year in the series	€ 8,446 Cash 2023: € 8,446 ▼ 92% vs 2022 (€ 102,426) Unfavourable step	€ 216,699 Cash 2024: € 216,699 ▲ € 208,253 vs 2023 (€ 8,446) Favourable step	€ 26,679 Cash 2025: € 26,679 ▼ 88% vs 2024 (€ 216,699) Unfavourable step	▼ 88%
Retained profit	€ 1,470,999 Retained profit 2022: € 1,470,999 First fiscal year in the series	€ 1,472,814 Retained profit 2023: € 1,472,814 Unchanged (€ 1,470,999) Favourable step	€ 1,143,409 Retained profit 2024: € 1,143,409 ▼ 22% vs 2023 (€ 1,472,814) Unfavourable step	€ 111,201 Retained profit 2025: € 111,201 ▼ 90% vs 2024 (€ 1,143,409) Unfavourable step	▼ 90%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 360,000 Dividend 2024: € 360,000 Unchanged (€ 0) Unchanged	€ 1,461,900 Dividend 2025: € 1,461,900 ▲ € 1.1 million vs 2024 (€ 360,000) Unchanged	▲ € 1.1 million
Balance sheet total	€ 2,431,475 Balance sheet total 2022: € 2,431,475 First fiscal year in the series	€ 2,433,898 Balance sheet total 2023: € 2,433,898 Unchanged (€ 2,431,475) Unchanged	€ 2,346,267 Balance sheet total 2024: € 2,346,267 ▼ 4% vs 2023 (€ 2,433,898) Unchanged	€ 1,633,662 Balance sheet total 2025: € 1,633,662 ▼ 30% vs 2024 (€ 2,346,267) Unchanged	▼ 30%

Key figures of PHARMATEL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to PHARMATEL?

What happened at PHARMATEL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 16, 2025 New annual accounts for financial year 2025: profit of € 429,692 (▲ € 399,097 vs 2024). Source: NBB ↗
2025 Harry Christiaens stepped down as director. NBB
2025 Lieven Van Vooren stepped down as director. NBB
2025 YACELO NV stepped down as director. NBB
2019 Harry Christiaens became a director. NBB
2019 Lieven Van Vooren became a director. NBB
2019 YACELO NV became a director. NBB
Jun 11, 2013 New establishment in Gent. KBO

In short

From € 31,804 profit in 2022 to € 429,692 profit in 2025.

Paid € 9,727 in corporate taxes since 2022.

Best year ever: 2025, with € 429,692 profit.

Paid out € 1.8 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

INGRIS 33.3%

The stake of INGRIS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMATEL

PHARMATEL IMMO BV 100%

The shares are held by INGRIS (33.3%). It owns 100% of PHARMATEL IMMO BV itself.

Directors

According to the 2025 annual accounts

Harry Christiaens

Director

Also active at: INGRIS

since 2019 · until 2025

Lieven Van Vooren

Director

since 2019 · until 2025

YACELO NV

Managing director · represented by LUDO TIELEN

Also active at: R.W.H., V.V. INVEST

since 2019 · until 2025

Shareholders

INGRIS

33.3%

Participations

PHARMATEL IMMO BV

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Surkelbulk 8

9051 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

INGRIS same network

€ 67,848 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0535.844.727

VAT number

BE 0535.844.727

Registered office

Surkelbulk 8, 9051 Gent

Names & denominations

PHARMATEL

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

11 June 2013

Peppol

Active · Active since 13 Feb 2026

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMATEL

Warning lights

Financials

What happened to PHARMATEL?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions